Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2004

01-11-2004

Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma

Authors: He-cheng Li, Dao-cheng Cao, Yi Liu, Yi-feng Hou, Jiong Wu, Jin-song Lu, Gen-hong Di, Gang Liu, Fang-ming Li, Zhou-luo Ou, Cui Jie, Zhen-zhou Shen, Zhi-ming Shao

Published in: Breast Cancer Research and Treatment | Issue 1/2004

Login to get access
Metadata
Title
Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma
Authors
He-cheng Li
Dao-cheng Cao
Yi Liu
Yi-feng Hou
Jiong Wu
Jin-song Lu
Gen-hong Di
Gang Liu
Fang-ming Li
Zhou-luo Ou
Cui Jie
Zhen-zhou Shen
Zhi-ming Shao
Publication date
01-11-2004
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/2004
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-004-1200-8

Other articles of this Issue 1/2004

Breast Cancer Research and Treatment 1/2004 Go to the issue

OriginalPaper

Clinicopathological feature and long-term prognosis of apocrine carcinoma of the breast in Japanese women

OriginalPaper

Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer

OriginalPaper

Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids

OriginalPaper

Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes

OriginalPaper

Frequent activation of CArG binding factor-A expression and binding in N-methyl-N-nitrosourea-induced rat mammary carcinomas

Report

Expression of FGF-2 alters focal adhesion dynamics in migration-restricted
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits